Sleep Apnea News and Research

RSS

Electroacupuncture at Lianquan point restores post-stroke swallowing function

Swallowing is a complex act requiring precise coordination of the mouth, throat, and voice box. After a stroke, damage to the brain's motor cortex can disrupt swallowing-related neural commands, leaving patients unable to clear food or liquid from their throat safely.

23 Jun 2026

Study identifies top predictors for weight loss using tirzepatide

One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

Study finds gaps in guideline-based testosterone prescribing practices

Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill, by Sophia Sinha, M.D., clinical assistant professor at the University of Michigan in Ann Arbor, Mich.

14 Jun 2026

GLP-1 therapy associated with more dizziness and fainting

Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications.

14 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Microbially modified bile acids influence sleep apnea outcomes

Studies in mice reveal a new target for potentially treating and preventing life-threatening cardiovascular complications in the millions of patients with sleep apnea worldwide.

7 Jun 2026

Review explores complex associations between sleep apnea and lung cancer

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent hypoxia and sleep fragmentation, which may contribute to lung cancer development and progression.

29 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

Positional therapy trains sleep apnea patients for long-term recovery

Positional therapy can be a long-lasting and effective treatment for patients with positional obstructive sleep apnea (OSA), according to research presented at the 2026 ATS International Conference.

20 May 2026

Early CPAP nonadherence does not predict long-term treatment failure

Many insurers stop covering continuous positive airway pressure or CPAP devices if patients don't use them regularly in the first 90 days.

20 May 2026

Researchers identity patients with exceptional tirzepatide response outcomes

Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally.

19 May 2026

Once-nightly oral pill helps control obstructive sleep apnea

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference.

18 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026

A new tool that predicts obesity-related disease risk beyond BMI

OBSCORE is a data-driven tool that identifies high-risk individuals for obesity-related diseases, enhancing treatment targeting beyond traditional BMI metrics.

5 May 2026

AHA calls for lifelong brain health strategy to prevent cognitive decline

The AHA scientific statement calls for a life-course approach to brain health that integrates cognitive, emotional, behavioral, vascular, environmental, inflammatory, sleep, microbiome, and social factors. It highlights how early-life exposures, mental health, pollution, chronic inflammation, poor sleep, gut dysbiosis, and socioeconomic adversity may shape brain resilience and later-life cognitive decline.

29 Apr 2026

New clinical guidelines significantly reduce opioid prescriptions after ear surgery

A new retrospective study published in OTO Open, the open-access journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF), demonstrates that the Clinical Practice Guideline (CPG) Opioid Prescribing for Analgesia After Common Otolaryngology Operations has had a measurable and sustained impact on prescribing practices following parotidectomy, which a surgical procedure to remove the parotid gland.

28 Apr 2026

New scientific statement defines brain health across life

Brain health isn't determined only by genetics or what happens later in life. A growing body of research shows that a range of factors-from mental health and sleep to environment, lifestyle and social conditions-play a powerful role in shaping how the brain functions and ages.

28 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

Advanced heart, kidney and metabolic disease linked to higher cancer risk

People with advanced heart, kidney and metabolic disease may face a higher risk of developing cancer, according to new research published today in the American Heart Association's peer-reviewed scientific journal Circulation: Population Health and Outcomes.

27 Apr 2026